SVB Leerink maintained its Sarepta Therapeutics [SRPT] rating to the equivalent of Outperform but changed the price target to $125.0 from $197, in a research note dated 2021-01-08. That figure represents around a -26.01% premium from where the company’s shares closed on Thursday. Some new analysts also started their coverage, with UBS’s analysts assigning the shares to “a Buy” rating in a research note to investors issued in late October. Meanwhile, Raymond James had launched its coverage on SRPT with “an Outperform”, in a research note produced for clients August 25, 2020. In addition, there was a downgrade from Credit Suisse on August 20, 2020. The rater changed SRPT from “an Outperform” to “a Neutral”.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Is Sarepta Therapeutics Inc. [NASDAQ:SRPT] a Good Buy Right Now?
It should be noted that SRPT technical indicators for short, intermediate as well as long term progress have placed an overall average of 88% as Buy. The average signal changed from 88% Buy in the last week and compares with 40% Buy in the past month. Data from Sarepta Therapeutics Inc.’s Trend Spotter indicated that the signals were Strongest. The stock current average is 1.05 million shares in the past 20 days and the short term average signal indicates a 50% Buy. In the last 50 days, the average trading volume was 0.89 million shares while the medium term average advocated for 100% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 0.78 million shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
SRPT Price Performance
On Wall Street, Sarepta Therapeutics Inc. [NASDAQ:SRPT] finished Thursday’s session up 1.50% at $168.95. The stock went up to $174.30 at the same session while its lowest single day price was $166.93. In the last five days, it saw a fall of about -1.51%, Sarepta Therapeutics Inc. shares dropped by almost -0.90% since the beginning of the year. However, the share price has dropped to as low as -7.08% below its one year high. On 01/04/21, the company shares recorded $174.49, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/06/21, the same year at $161.12. The company’s shares have inclined by 29.93% in the past year. The 50-day SMA achieved is $152.17 while the 200-day SMA is $144.66. Volume gained to 4.75 million from 0.91 million in the previous session.
SRPT Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 165.82 level, and in case of violation of this particular level, it will cause more drop to 162.69 level. On the upper level, 177.43 is still the key resistance. The stock may increase to the subsequent resistance at 173.19. The Relative Strength Index (RSI) pinned on the 14-day chart is 57.54, implying a neutral technical stance while the MACD stands at -5.47, meaning price will decrease in the next trading period. Percent R indicator moved to 62.19%, implying low price movement. Stochastic %K at 24.93% suggest selling the stock.
What is the short interest in Sarepta Therapeutics Inc.?
Short interest in the Sarepta Therapeutics Inc. stock has surged, increasing by 0.36 million shares to total 7.91 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 8.27 million, data from Yahoo Finance shows. The decrease of -4.55% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 11.85% of the overall float for the stock.
Sarepta Therapeutics Inc.’s Biggest Shareholders: Who Owns Sarepta Therapeutics Inc. [SRPT]?
Filings by The Vanguard Group, Inc. showed that the firm now holds a total of 6,907,344 shares or roughly 8.75% of the outstanding SRPT shares. This means their shares have reduced by -61,716 from the 6,907,344 the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, Capital Research & Management Co updated stake is worth $945,357,099. Details in the latest 13F filings reveal that Fidelity Management & Research Co disposed off their -20.24% stake valued at $777,841,034 while BlackRock Fund Advisors cut theirs at $569,298,227. During the last quarter, Fidelity Management & Research Co liquidated -1,401,047 of its shares in Sarepta Therapeutics Inc. while BlackRock Fund Advisors sold -116,308 shares. The Janus Capital Management LLC’s holdings currently number 3,950,552 shares at $667445760.4. According to the firm’s last 13F report, Jennison Associates LLC shares in the company at filing stood at 2,605,072 shares, roughly $366,950,442.
SRPT Earnings Forecast For The Current Quarter
Sarepta Therapeutics Inc. [SRPT] is expected to report strong earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $148.68M and an earnings per share of -$1.8 for Dec 2020. Looking further ahead, the company is expected to report revenue of $157.85M at an EPS of -$1.53 for Mar 2021. The estimates represent upside of 42.80% and 24.00% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
SRPT Earnings Estimates For The Current Year
For the financial year, Sarepta Therapeutics Inc. [NASDAQ:SRPT] is expected to bring in revenue of $541.72M. The returns are nearly $160.89 million higher than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -6.7, higher than that of FY19 by $3.01. Estimates put this year’s earnings growth at 31.00%, 24.90% for the next, and at an annual 96.00% over the next 5-year period. As for sales, forecasts are for an increase of 42.20% in the current fiscal year and a further 42.80% over the following year.